西达本胺维持治疗预防外周T细胞淋巴瘤自体造血干细胞移植术后复发的临床观察

刘红云; 董松; 曾韫璟; 高力; 张曦

doi:10.16016/j.1000-5404.202006020

您当前的位置：

首页 >

文章列表页 >

西达本胺维持治疗预防外周T细胞淋巴瘤自体造血干细胞移植术后复发的临床观察

专题报道:血液肿瘤诊治新策略与临床应用 | 更新时间：2026-01-09

- 西达本胺维持治疗预防外周T细胞淋巴瘤自体造血干细胞移植术后复发的临床观察
- Maintenance therapy with chidamide prevents from postoperative recurrence after autologous hematopoietic stem cell transplantation for peripheral T cell lymphoma
- 第三军医大学学报 2020年42卷第17期页码：1724-1729
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.16016/j.1000-5404.202006020
  中图分类号：
- 收稿：2020-06-02，
  
  纸质出版：2020-09-15
- 稿件说明：
移动端阅览
刘红云, 董松, 曾韫璟, 等. 西达本胺维持治疗预防外周T细胞淋巴瘤自体造血干细胞移植术后复发的临床观察[J]. 第三军医大学学报, 2020,42(17):1724-1729.

Hongyun LIU, Song DONG, Yunjing ZENG, et al. Maintenance therapy with chidamide prevents from postoperative recurrence after autologous hematopoietic stem cell transplantation for peripheral T cell lymphoma[J]. Journal of Third Military Medical University, 2020, 42(17): 1724-1729.
刘红云, 董松, 曾韫璟, 等. 西达本胺维持治疗预防外周T细胞淋巴瘤自体造血干细胞移植术后复发的临床观察[J]. 第三军医大学学报, 2020,42(17):1724-1729. DOI： 10.16016/j.1000-5404.202006020.

Hongyun LIU, Song DONG, Yunjing ZENG, et al. Maintenance therapy with chidamide prevents from postoperative recurrence after autologous hematopoietic stem cell transplantation for peripheral T cell lymphoma[J]. Journal of Third Military Medical University, 2020, 42(17): 1724-1729. DOI： 10.16016/j.1000-5404.202006020.

摘要

Abstract

Objective

To investigate the efficacy and safety of chidamide maintenance therapy in prevention of the recurrence of peripheral T-cell lymphoma after autologous peripheral blood stem cell transplantation (auto-PBSCT).

Methods

A retrospective study was carried out on 49 patients with peripheral T-cell lymphoma undergoing auto-PBSCT in our medical center from January 2017 to May 2018. According to whether receiving chidamide maintenance treatment after transplantation or not

they were divided into experimental group (

=23) and control group (

=26). The patients from the former group were given chidamide maintenance tr

eatment

by taking orally 30 mg/time

twice/week

in an interval not less than 3 d

30 min after breakfast

initiating from 30 to 45 d after transplantation. While those of the control group got no maintenance treatment

but were only examined and followed up regularly after transplantation. The main outcome measure was to observe the recurrence rate between these 2 groups in 2 years after transplantation. The secondary indicator was the differences in 1-year recurrence rate

1- and 2-year progression free survival (PFS)

and 2-year overall survival (OS) between them. The adverse effects of chidamide were observed during the maintenance treatment.

Results

Until the last follow-up of May 2020

the 2-year recurrence rate was only 39.1% in the experimental group

which was significantly lower than that of the control group (69.2%

=0.047). In 1 year after transplantation

5 patients (21.7%) in the experimental group and 14 patients (53.8%) in the control group had recurrence

with that in the control group significantly higher than that in the experimental group (

=0.039). The 1-year PFS was significantly better in the experimental group than the control group

but there was no significant difference in the 1-year OS between them. The experimental group also obtained better 2-year PSF and OS rates than the control group. No correlations were observed in the recurrence rate of citabenamine maintenance therapy with age

gender

pathological type

clinical stage

bone marrow invasion

and International Prognostic Index (IPI) score respectively (

0.05). However

incomplete remission and elevated LDH level before transplantation were risk factors for poor prognosis (

0.05). The main adverse reactions of chidamide maintenance therapy were hematological adverse reactions in 10 cases

fatigue in 5 cases

digestive tract adverse reactions in 4 cases

and both mild damage to liver and kidney functions and thrombosis i

n 1 case. No adverse cardiac effect was found in 1 case.

Conclusion

Chidamide maintenance therapy reduces the recurrence of peripheral T cell lymphoma after auto-PBSCT

with good safety.

关键词

Keywords

references

SWERDLOW S H CAMPO E PILERI S A The 2016 revision of the World Health Organization classification of lymphoid neoplasms Blood 2016 127 20 2375 2390 10.1182/blood-2016-01-643569 SWERDLOW S H, CAMPO E, PILERI S A, et al . The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J ] . Blood, 2016, 127(20): 2375-2390. DOI:10.1182/blood-2016-01-643569.

ABOUYABIS A N SHENOY P J SINHA R A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma ISRN Hematol 2011 2011 623924 10.5402/2011/623924 ABOUYABIS A N, SHENOY P J, SINHA R, et al . A systematic review and meta-analysis of front-line anthracycline-based chemotherapy r egimens for peripheral T-cell lymphoma[J ] . ISRN Hematol, 2011, 2011: 623924. DOI:10.5402/2011/623924.

ABOUYABIS A N SHENOY P J LECHOWICZ M J Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States Leuk Lymphoma 2008 49 11 2099 2107 10.1080/10428190802455867 ABOUYABIS A N, SHENOY P J, LECHOWICZ M J, et al . Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States[J ] . Leuk Lymphoma, 2008, 49(11): 2099-2107. DOI:10.1080/10428190802455867.

ESCALÓN M P LIU N S YANG Y Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience Cancer 2005 103 10 2091 2098 10.1002/cncr.20999 ESCALÓN M P, LIU N S, YANG Y, et al . Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience[J ] . Cancer, 20 05, 103(10): 2091-2098. DOI:10.1002/cncr.20999.

REIMER P RÜDIGER T GEISSINGER E Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study J Clin Oncol 2009 27 1 106 113 10.1200/JCO.2008.17.4870 REIMER P, RÜDIGER T, GEISSINGER E, et al . Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study[J ] . J Clin Oncol, 2009, 27(1): 106-113. DOI:10.1200/JCO.2008.17.4870.

SHI Y K JIA B XU W Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China J Hematol Oncol 2017 10 1 69 10.1186/s13045-017-0439-6 SHI Y K, JIA B, XU W, et al . Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China[J ] . J Hematol Oncol, 2017, 10(1): 69. DOI:10.1186/s13045-01 7-0439-6.

马军石远凯朱军西达本胺治疗外周T细胞淋巴瘤中国专家共识(2018版) 中国肿瘤临床 2018 45 15 763 768 10.3969/j.issn.1000-8179.2018.15.531 马军, 石远凯, 朱军, 等.西达本胺治疗外周T细胞淋巴瘤中国专家共识(2018版)[J].中国肿瘤临床, 2018, 45(15):763-768.DOI: 10.3969/j.issn.1000-8179.2018.15.531.

MA J SHI Y K ZHU J Consensus of Chinese experts on the treatment of peripheral T-cell lymphoma with chidamide (2018) Chin J Clin Oncol 2018 45 15 763 768 10.3969/j.issn.1000-8179.2018.15.531 MA J, SHI Y K, ZHU J, et al . Consensus of Chinese experts on the treatment of peripheral T-cell lymphoma with chidamide (2018) [J ] .Chin J Clin Oncol, 2018, 45(15):763-768.DOI: 10.3969/j.issn.1000-8179.2018.15.531.

U.S. Department of Health and Human Services . National Institutes of Health National Cancer Institute. Common terminology criteria for adverse events (CTCAE) Version 5.0 [S/OL ] . ( 2017-11-27 ). [ 2020-03-20 ] . https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf. U.S. Department of Health and Human Services. National Institutes of Health National Cancer Institute. Common terminology criteria for adverse events (CTCAE) Version 5.0[S/OL]. (2017-11-27). [2020-03-20]. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf.

PILERI S A PICCALUGA P P New molecular insights into peripheral T cell lymphomas J Clin Invest 2012 122 10 3448 3455 10.1172/JCI61205 PILERI S A, PICCALUGA P P. New molecular insights into peripheral T cell lymphomas[J]. J Clin Invest, 2012, 122(10): 3448-3455. DOI:10.1172/JCI61205.

林凌宋腾张亚瑞 Hyper-CVAD/MA和CHOP方案治疗外周T细胞淋巴瘤非特指型的78例临床分析中国肿瘤临床 2016 43 11 486 492 10.3969/j.issn.1000-8179.2016.11.370 林凌, 宋腾, 张亚瑞, 等. Hyper-CVAD/MA和CHOP方案治疗外周T细胞淋巴瘤非特指型的78例临床分析[J].中国肿瘤临床, 2016, 43(11): 486-492.

LIN L SONG T ZHANG Y R Clinical analysis of hyper-CVAD/MA regimen and CHOP/CHOP-like regimen in the treatment of 78 patients with peripheral T-cell lymphoma, not otherwise specified (PT-CL-NOS) Chin J Clin Oncol 2016 43 11 486 492 10.3969/j.issn.1000-8179.2016.11.370 LIN L, SONG T, ZHANG Y R, et al . Clinical analysis of hyper-CVAD/MA regimen and CHOP/CHOP-like regimen in the treatment of 78 patients with peripheral T-cell lymphoma, not otherwise specified (PT-CL-NOS)[J ] . Chin J Clin Oncol, 2016, 43(11): 486-492. DOI:10.3969/j.issn.1000-8179.2016.11.370.

王春红金鑫李景贺西达本胺治疗以RS3PE综合征为表现的血管免疫母细胞性T细胞淋巴瘤获部分缓解1例临床肿瘤学杂志 2018 23 1 89 92 10.3969/j.issn.1009-0460.2018.01.016 王春红, 金鑫, 李景贺, 等.西达本胺治疗以RS3PE综合征为表现的血管免疫母细胞性T细胞淋巴瘤获部分缓解1例[J].临床肿瘤学杂志, 2018, 23(1): 89-92.DOI:10.3969/j.issn.1009-0460.2018.01.016.

WANG C H JIN X LI J H A case of partial remission of vascular immunoblastic T-cell lymphoma with RS3PE syndrome treated with xidabamide Chin Clin Oncol 2018 23 1 89 92 10.3969/j.issn.1009-0460.2018.01.016 WANG C H, JIN X, LI J H, et al . A case of partial remission of vascular immunoblastic T-cell lymphoma with RS3PE syndrome treated with xidabamide[J ] . Chin Clin Oncol, 2018, 23(1): 89-92. DOI:10.3969/j.issn.1009-0460.2018.01.016.

YARED J KIMBALL A The role of high dose chemotherapy and autologous stem-cell transplantation in peripheral T-cell lymphoma: a review of the literature and new perspectives Cancer Treat Rev 2013 39 1 51 59 10.1016/j.ctrv.2012.03.011 YARED J, KIMBALL A. The role of high dose chemotherapy and autologous stem-cell transplantation in peripheral T-cell lymphoma: a review of the literature and new perspectives[J]. Cancer Treat Rev, 2013, 39(1): 51-59. DOI:10.1016/j.ctrv.2012.03.011.

COIFFIER B PRO B PRINCE H M Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy J Clin Oncol 2012 30 6 631 636 10.1200/JCO.2011.37.4223 COIFFIER B, PRO B, PRINCE H M, et al . Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy[J ] . J Clin Oncol, 2012, 30(6): 631-636. DOI:10.1200/JCO.2011.37.4223.

O'CONNORO O A HORWITZ S MASSZI T Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase Ⅱ BELIEF (CLN-19) study J Clin Oncol 2015 33 23 2492 2499 10.1200/JCO.2014.59.2782 O'CONNOR O A, HORWITZ S, MASSZI T, et al . Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase Ⅱ BELIEF (CLN-19) study[J ] . J Clin Oncol, 2015, 33(23): 2492-2499. DOI:10.1200/JCO.2014.59.2782.

付金月王树叶外周T细胞淋巴瘤应用西达本胺治疗疗效及预后因素分析临床血液学杂志 2018 31 7 531 534 10.13201/j.issn.1004-2806.2018.07.010 付金月, 王树叶.外周T细胞淋巴瘤应用西达本胺治疗疗效及预后因素分析[J].临床血液学杂志, 2018, 31(7): 531-534.DOI:10.13201/j.issn.1004-2806.2018.07.010.

FU J Y WANG S Y Analysis of therapy and prognostic factors of chidamide in the treatment of peripheral T-cell lymphoma J Clin Hematol 2018 31 7 531 534 10.13201/j.issn.1004-2806.2018.07.010 FU J Y, WANG S Y. Analysis of therapy and prognostic factors of chidamide in the treatment of peripheral T-cell lymphoma[J]. J Clin Hematol, 2018, 31(7): 531-534. DOI:10.13201/j.issn.1004-2806.2018.07.010.

王明李雪王字玲基于表观遗传学的抗肿瘤药物研究进展国际药学研究杂志 2016 43 4 658 664 10.13220/j.cnki.jipr.2016.04.013 王明, 李雪, 王字玲.基于表观遗传学的抗肿瘤药物研究进展[J].国际药学研究杂志, 2016, 43(4): 658-664.

WANG M LI X WANG Z L Epigenetics-based anticancer drugs: research advances J Int Pharm Res 2016 43 4 658 664 10.13220/j.cnki.jipr.2016.04.013 WANG M, LI X, WANG Z L. Epigenetics-based anticancer drugs: research advances[J]. J Int Pharm Res, 2016, 43(4): 658-664. DOI:10.13220/j.cnki.jipr.2016.04.013.

YAO Y S ZHOU J H WANG L X Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine PLoS ONE 2013 8 8 e70522 10.1371/journal.pone.0070522 YAO Y S, ZHOU J H, WANG L X, et al . Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine[J ] . PLoS ONE, 2013, 8(8): e70522. DOI:10.1371/journal.pone.0070522.

SHI Y DONG M HONG X Results from a multicenter, open-label, pivotal phase Ⅱ study of chidamide in relapsed or refractory peripheral T-cell lymphoma Ann Oncol 2015 26 8 1766 1771 10.1093/annonc/mdv237 SHI Y, DONG M, HONG X, et al . Results from a multicenter, open-label, pivotal phase Ⅱ study of chidamide in relapsed or refractory peripheral T-cell lymphoma[J ] . Ann Oncol, 2015, 26(8): 1766-1771. DOI:10.1093/annonc/mdv237.

MOURAD N MOUNIER N BRIÈRE J Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials Blood 2008 111 9 4463 4470 10.1182/blood-2007-08-105759 MOURAD N, MOUNIER N, BRIÈRE J, et al . Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials[J ] . Blood , 2008, 111(9): 4463-4470. DOI:10.1182/blood-2007-08-105759.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

西达本胺联合吗替麦考酚酯抑制继发性急性髓系白血病细胞增殖

晚期肺腺癌患者维持治疗中EGFR-TKI联合贝伐珠单抗的回顾性分析

卡培他滨或贝伐单抗用于结直肠癌维持治疗的回顾性分析

自体造血干细胞移植治疗复发、难治性经典型霍奇金淋巴瘤的疗效观察

自体造血干细胞移植期间腹泻患者艰难梭菌感染及其影响因素分析